LONDON (Alliance News) - TyraTech Inc Wednesday said it had secured listings for its Vamousse headlice treatment in the second-largest pharmacy chain in the US, continuing a run of success in getting the product into key chains in both the US and UK.
It also said the UK's largest retailer, Tesco PLC, will start selling Vamousse on its open shelves as well as through its pharmacy counters, making it more accessible to customers.
The deal in the US is with CVS Pharmacy, which is the second largest pharmacy chain in the country after Walgreens, with more than 7,600 stores and 100 million customers each year. TyraTech said it expects that its Vamousse Treatment product will be available in the majority of CVS stores in the US from the end of April.
The company recently secured listing for Vamousse with the three largest distributors of pharmaceutical products in the US: McKesson, AmerisourceBergen and Cardinal Health, giving it access to the roughly 20,000 independent pharmacies in the US.
In the UK, it has recently won deals to sell its Vamousse head lice treatment and protection products in Lloyds Pharmacies and the treatment product with the Day Lewis Pharmacy chain.
"The CVS listing is probably our most important milestone this year as it firmly establishes our product in the pharmacy segment in the US and significantly enhances the profile of our brand,2 TyraTech Chief Executive Bruno Jactel said in a statement.
TyraTech shares were flat at 5.25 pence in London Wednesday morning.
By Steve McGrath; stevemcgrath@alliancenews.com; @stevemcgrath1
Copyright 2015 Alliance News Limited. All Rights Reserved.
